Applied BioMath, LLC Launches Software Product for the Early

Applied BioMath, LLC Launches Software Product for the Early Feasibility Assessment of Biotherapeutics


Applied BioMath, LLC Launches Software Product for the Early Feasibility Assessment of Biotherapeutics
Applied BioMath announces the release of Applied BioMath Assess™, an interactive, web-based application that helps project leaders, protein engineers and chemists, and modelers assess the difficulties and risks in developing a biotherapeutic.
News provided by
Share this article
Share this article
CONCORD, Mass., April 6, 2021 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, announced today the launch of Applied BioMath Assess™, an early feasibility assessment tool for biotherapeutics.  Applied BioMath Assess is an interactive, web-based application that helps project leaders, protein engineers and chemists, and modelers assess the difficulties and risks in developing a biotherapeutic very early-on in a project.   "Applied BioMath Assess was an essential step for our portfolio prioritization.   We had several therapeutics under consideration and needed to understand what parameter ranges were required to achieve our desired outcomes," said David de Graaf, PhD, Co-Founder of Tuned Therapeutics.  "Being able to quickly analyze each therapeutic helped us identify which therapeutics were best to pursue and ultimately helped us de-risk our portfolio and provide a clear and scientific rationale with our stakeholders."

Related Keywords

John Desjarlais , John Burke , , Applied Biomath Assess , Biomath Assess , David De Graaf , Target Engagement , Applied Biomath , ஜான் சேஜர்லைஸ் , ஜான் பர்க் , டேவிட் டி கிராஃப் , இலக்கு நிச்சயதார்த்தம் ,

© 2025 Vimarsana